NEUP
Neuphoria Therapeutics Inc.

532
Loading...
Loading...
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
24

Frequently Asked Questions

What is Market Cap of Neuphoria Therapeutics Inc.?
What is the 52-week high for Neuphoria Therapeutics Inc.?
What is the 52-week low for Neuphoria Therapeutics Inc.?
What is Neuphoria Therapeutics Inc. stock price today?
What was Neuphoria Therapeutics Inc. stock price yesterday?
What is the PE ratio of Neuphoria Therapeutics Inc.?
What is the Price-to-Book ratio of Neuphoria Therapeutics Inc.?
What is the 50-day moving average of Neuphoria Therapeutics Inc.?
How many employess does Neuphoria Therapeutics Inc. has?

Latest NEUP News

View

Advertisement. Remove ads.

Advertisement. Remove ads.